Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2922083 · 1 trial · 1 indication
Events deemed by the Investigator to be SAEs related to study drug administration are reported. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| Placebo (Part A) | PLACEBO_COMPARATOR | Single oral dose of placebo administered to healthy participants in up to 1 of 3 study periods in Part A |
| LY2922083 (Part A) | EXPERIMENTAL | Single ascending dose of LY2922083 (starting at 0.5 milligrams \[mg\]) administered orally to healthy participants in up to 2 of 3 study periods in Part A |
| Placebo (Part B) | PLACEBO_COMPARATOR | Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B |
| LY2922083 (Part B) | EXPERIMENTAL | Single ascending dose of LY2922083 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Administered orally as capsules |
| LY2922083 | DRUG | Administered orally as capsules |
Inclusion Criteria: For all participants : * Must be a male, or a female who cannot become pregnant, and who is either a healthy participant, or who has type 2 diabetes * Have a screening body mass index (BMI) of at least 18.0 kilograms per square meter (kg/m\^2) * Have blood pressure, pulse rate,...
LY2922083 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is being developed by Eli Lilly and Company as a potential therapy for this metabolic condition, though it is still in early clinical development and not yet approved.
LY2922083 is a small molecule developed by Eli Lilly and Company for Type 2 Diabetes Mellitus. The specific molecular target of LY2922083 has not been disclosed, so its exact mechanism of action is not publicly detailed. It is being evaluated in clinical trials for its potential effects on diabetes.
LY2922083 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The drug is an investigational small molecule intended for the treatment of Type 2 Diabetes Mellitus.
LY2922083 is in Phase 1 clinical development. It has completed one Phase 1 trial, and it remains an investigational drug that has not been approved by regulatory authorities. Further clinical studies would be needed to assess its safety and efficacy.
LY2922083 has been studied in one completed Phase 1 clinical trial, identified as NCT01748552. This trial, titled "A Study of LY2922083 in Healthy Participants and Participants With Diabetes," enrolled 36 participants with Type 2 Diabetes Mellitus in Singapore. The trial was placebo-controlled and randomized.
LY2922083 is an investigational drug candidate developed by Eli Lilly and Company. No alternative names or brand names have been associated with this compound in the available clinical trial information. It is identified solely by its development code LY2922083.